A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With HR+, HER2- Advanced Breast Cancer
TerSera Therapeutics LLC · Advanced Breast Cancer
Phase 1
Recruiting
88
2026-07
Industry sponsor intelligence
TerSera Therapeutics LLCClinical Pipeline.
Lead-sponsor view of TerSera Therapeutics LLC's indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 1
- Recruiting
- 1
- Active
- 0
- Completed
- 0
- Results posted
- 0
- Avg enrollment
- 88
Pipeline overview
Programs by phase and activity.
Velocity
TerSera Therapeutics LLC trials by start year
Study start year · indexed snapshot
Development
Trials by phase
1phase labels
Early Phase 10
Phase 11
Phase 20
Phase 30
Phase 40
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Goserelin → | 1 | 1 | 0 | 0 | 0 | 1 |
Active peptide trials
In motion now.
NCT IDStudyPhase / statusEnrollmentUpdated
Completed trials
Finished registry records.
No studies in this snapshot.
Search sponsor records
All TerSera Therapeutics LLC studies.
This page groups studies where TerSera Therapeutics LLC is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
1 matching study
Last registry update first